SCHEMBL3083362

SCHEMBL3083362

CC(Oc1nsc(NC(=O)NCCc2cnc[nH]2)c1C(N)=O)c1cccc(F)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 5/20 0.43
HTR3B O95264 5/20 0.43
HTR3A P46098 5/20 0.43
HTR3D Q70Z44 5/20 0.43
HTR3C Q8WXA8 5/20 0.43
KMT2A Q03164 4/20 0.39
MEN1 O00255 2/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38
LMNA P02545 1/20 0.38
ACVR2A P27037 1/20 0.37
TGFBR2 P37173 1/20 0.37
QPCT Q16769 1/20 0.36
QPCTL Q9NXS2 1/20 0.36
ITGB2 P05107 1/20 0.36
ICAM1 P05362 1/20 0.36
ITGAL P20701 1/20 0.36
KDR P35968 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3094182 0.84 KDR (0.49) ACVR2ATGFBR2KDRPLK4AURKA
SCHEMBL4852237 0.77 HTR3E (0.44) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL3077749 0.77 KDR (0.51) ACVR2ATGFBR2KDRPLK4AURKA
SCHEMBL3093955 0.77 KDR (0.42) KDRPLK4AURKAEPHB6RIPK2
SCHEMBL3090347 0.76 KDR (0.45) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL3083357 0.75 HTR3E (0.43) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL3073620 0.75 ACVR2A (0.41) LMNAACVR2ATGFBR2KDRPLK4
SCHEMBL3089348 0.75 KDR (0.38) LMNAACVR2ATGFBR2KDRPLK4
SCHEMBL3078323 0.74 KDR (0.51) HTR3ACYP2D6KDRPLK4AURKA
SCHEMBL3086887 0.74 KDR (0.40) KMT2AMEN1CYP2D6ACVR2ATGFBR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790902-B2 Isothiazole derivatives useful as anticancer agents PFIZER, INC. (US) 2010-09-07 US disclosed
US-20080300249-A1 tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents PFIZER, INC. (US) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300249-A1 tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents CDKN1A, TK1, CDK1 HTR3E 2567/4885HTR3B 2911/4885HTR3A 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.